<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151943">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01122030</url>
  </required_header>
  <id_info>
    <org_study_id>1007V9214</org_study_id>
    <nct_id>NCT01122030</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of S-297995 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety and Efficacy of S-297995 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study consists of 6 treatment cohorts of 12 subjects with chronic pain, opioid-induced bowel
      dysfunction, and opioid physical dependence. Total duration of treatment for each subject
      will be up to 28 days.

      Each subject will receive a single dose of study drug, administered orally in the morning of
      Day 15 under fasted conditions.

      Cohort 1: 0.1 mg of S-297995 or placebo. Cohort 2: 0.3 mg of S-297995 or placebo. Cohort 3:
      1 mg of S-297995 or placebo. Cohort 4: 3 mg of S-297995 or placebo. Cohort 5: 0.03 mg of
      S-297995 or placebo. Cohort 6: 0.01 mg of S-297995 or placebo.

      The primary objective of the study is to evaluate the safety of single doses of oral
      S-297995 in subjects physically dependent on opioids
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single dose of S-297995 or matching placebo will be administered orally to each cohort of
      12 subjects (9 treatments, 3 placebos) in the morning of Day 15 under fasted conditions. The
      first cohort will receive a 0.1 mg dose. Cohorts will continue to be enrolled at the next
      higher dose level until the highest dose level (3 mg) has been achieved or until the study
      is discontinued due to adverse events or Clinical Opioid Withdrawal Score of &gt;8. A 0.03 mg
      dose will also be tested. A 0.01 mg dose will be tested if 4 or more subjects experience 1
      or more bowel movements within the 24 hour period post dose in the 0.03 mg dosing cohort
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety of single doses of oral S-297995 in subjects physically dependant on opioids.</measure>
    <time_frame>24 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate incidence of signs and symptoms of withdrawal syndrome</measure>
    <time_frame>24 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of S-297995 on opioid-induced bowel dysfunction</measure>
    <time_frame>17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetic profile of S-297995 and its metabolites with opioid treatment</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the optimal dose of S-297995</measure>
    <time_frame>24 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Opioid Induced Bowel Dysfunction</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental drug or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental drug or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental drug or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental drug or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental drug or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental drug or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1 mg of S-297995 or placebo</intervention_name>
    <description>One tablet of 0.1 mg of S-297995 or one tablet of placebo</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3 mg of S-297995 or placebo</intervention_name>
    <description>Three tablets of 0.1 mg of S-297995 or three tablets of placebo</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 mg of S-297995 or placebo</intervention_name>
    <description>One tablet of 1 mg of S-297995 or one tablet of placebo</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 mg of S-297995 or placebo</intervention_name>
    <description>Three tablets of 1 mg of S-297995 or three tablets of placebo</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.03 mg of S-297995 or placebo</intervention_name>
    <description>Oral solution (18 ml) containing 0.03 mg of S-297995 or 18 ml of sterile water containing placebo</description>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.01 mg of S-297995 or placebo</intervention_name>
    <description>Oral solution (6 ml) containing 0.01 mg of S-297995 or 6 ml of sterile water containing placebo</description>
    <arm_group_label>Cohort 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Understand and sign an informed consent form

          -  Males will agree to use an approved double-barrier method of contraception from Day 1
             until 1 month after study completion

          -  Subject tests negative on urine drug test unless the subject has a prescription for
             the drug(s) that test positive

        Exclusion Criteria:

          -  Subjects under opioid therapy for cancer-related pain or for the management of drug
             addiction

          -  Fecal incontinence, irritable bowel syndrome, inflammatory bowel disease, or other
             active medical disorders associated with diarrhea, intermittent loose stools, or
             constipation

          -  Subjects who have participated in any other investigational drug study within 30 days
             prior to Day 1

          -  Prior exposure to S-297995
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lifetree Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <lastchanged_date>September 13, 2011</lastchanged_date>
  <firstreceived_date>May 10, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Shionogi Clinical Trials Administrator</name_title>
    <organization>Shionogi</organization>
  </responsible_party>
  <keyword>Chronic pain</keyword>
  <keyword>Opioid physical dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
